# Plasma cell dyscrasias

Plasma cell dyscrasias are a heterogeneous group of disorders caused by the monoclonal proliferation of plasma cells in the bone marrow. Multiple myeloma is the most prevalent plasma cell dyscrasia and the second most frequent hematologic malignancy. Other plasma cell dyscrasias include monoclonal gammopathy of undetermined significance, solitary plasmacytoma, AL amyloidosis, POEMS syndrome, and heavy-chain diseases.

**Filter by content:**

- **Types**  
  AL amyloidosis  
  BRAF  
  Chromosomal aberrations  
  COVID-19  
  Deletion 13q  
  Deletion 17p  
  Deletion 1p  
  Favorable-risk  
  Gain 1q  
  High-risk  
  KRAS  
  MGC  
  MGRS  
  MM-related mutations  
  MYC  
  Newly diagnosed multiple myeloma  
  NRAS  
  PCL-like MM  
  Plasma cell dyscrasias  
  Plasma cell leukemia  
  Relapsed/refractory multiple myeloma  
  Risk  
  Smoldering multiple myeloma  
  Solitary plasmacytoma  
  TP53  
  Translocation (11;14)  
  Translocation (14;16)  
  Translocation (14;20)  
  Translocation (4;14)  
  Transplant-ineligible MM  
  Trisomy 21

**Therapeutics**  
  Acalabrutinib  
  ALLO-501  
  ALLO-605  
  ALLO-647  
  ALLO-715  
  Allo-HSCT  
  Allo-NKT  
  Alnuctamab  
  AMG 420  
  AMG 701  
  Anakinra  
  Anitocabtagene autoleucel  
  Anselamimab  
  Antibody recruiting molecules  
  Antibody therapy  
  AO-176  
  ARI0002h  
  Arlocabtagene autoleucel  
  Atezolizumab  
  Auto-HSCT  
  Auto-NKT  
  Avelumab  
  bb21217  
  BCL-2 inhibitors  
  BCMA CAR-T  
  Belantamab mafodotin  
  Bendamustine  
  BHV-1100  
  Binimetinib  
  Birtamimab  
  Blinatumomab  
  Bortezomib  
  Busulfan  
  CAEL-101  
  CAR NK cells  
  CAR therapy  
  Carfilzomib  
  CART-dd  
  BCMACB-011  
  CC-92480  
  CC-93269  
  CC-95266  
  CD138 CAR-T  
  CD19 CAR-T  
  Cellular therapy  
  Cemsidomide  
  Cevostamab  
  CFT7455  
  Checkpoint inhibitors  
  Chemotherapy  
  Ciltacabtagene autoleucel  
  Clodronate  
  Conjugated antibodies  
  CS1 (SLAMF7) CAR-T  
  Cyclophosphamide  
  Daratumumab  
  Dasatinib  
  Denosumab  
  Descartes-11  
  Dexamethasone  
  Doxorubicin  
  Durvalumab  
  Elotuzumab  
  Elranatamab  
  EM801  
  Encorafenib  
  Equecabtagene Autoleucel  
  Etentamig  
  Etoposide  
  Fludarabine  
  Forimtamig  
  GC012F  
  Gemcitabine  
  HBI0101  
  HDAC inhibitors  
  HDP-101  
  HPN217  
  Iberdomide  
  IBI3003  
  Ibrutinib  
  Idecabtagene vicleucel  
  Immune modulators  
  Inobrodib  
  Iopofosine I 131  
  Isatuximab  
  ISB 1342  
  ISB 1442  
  ISB 2001  
  Ixazomib  
  KLN-1010  
  KMCARLBL-034  
  Lenalidomide  
  Linvoseltamab  
  MCARH109  
  MEDI2228  
  Melflufen  
  Melphalan  
  Mezigdomide  
  Modakafusp alfa

**Congresses**  
  2021 Symposium  
  2022 Symposium  
  2023 Hub event  
  2024 Symposium  
  AACR 2020  
  AACR 2023  
  American Society of Hematology  
  ASCO 2017  
  ASCO 2018  
  ASCO 2019  
  ASCO 2020  
  ASCO 2021  
  ASCO 2022  
  ASCO 2023  
  ASCO 2024  
  ASCO 2025  
  ASCO 2026  
  ASH 2017  
  ASH 2018  
  ASH 2019  
  ASH 2020  
  ASH 2021  
  ASH 2022  
  ASH 2023  
  ASH 2024  
  ASH 2025  
  CAR-T 2020  
  CAR-T 2021  
  CAR-T 2022  
  CAR-T 2023  
  CAR-T 2024  
  CAR-T 2025  
  COMy 2018  
  COMy 2019  
  COMy 2020  
  COMy 2021  
  COMy 2022  
  COMy 2023  
  Controversies in Multiple Myeloma  
  EBMT 2019  
  EBMT 2020  
  EBMT 2021  
  EBMT 2022  
  EBMT 2023  
  EBMT 2024  
  EHA 2017  
  EHA 2018  
  EHA 2019  
  EHA 2020  
  EHA 2021  
  EHA 2022  
  EHA 2023  
  EHA 2024  
  EHA 2025  
  EHA 2026  
  EMN 2021  
  EMN 2022  
  EMN 2024  
  ESH 2017  
  ESH 2018  
  ESH 2019  
  ESH 2020  
  ESH 2021  
  ESH 2024  
  ESMO 2022  
  European Hematology Association  
  European Society for Blood and Marrow Transplantation  
  IACH 2024  
  IMS 2022  
  IMS 2023  
  IMS 2024  
  IMS 2025  
  IMS Workshop 2023  
  IMS Workshop 2024  
  IMW 2019  
  IMW 2021